Floatz logo

Idarubicine

Acute Lymphoblastic Leukemia

Xianmin Song, MDPhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
65/ 100

Competitive context

252 Active assets in the Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Gm-Csf
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs
Fred Hutchinson Cancer Center
Phase 2/3BBB
Equine Atg
Instituto Nacional de Cancer, Brazil
Phase 3BBB
THIOGUANINE ANHYDROUS
St. Jude Children's Research Hospital
Phase 4BBB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →